Steven J Isakoff

27PUBLICATIONS

206CO-AUTHORS

Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsMedical devices

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (27)

Sort by Publication Date:

|Jul 02, 2026

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

|Oct 27, 2025

Leveraging real-world evidence to personalize adjuvant therapy in HR+/HER2- early breast cancer.

Yael Bar, Steven J Isakoff, Seth A Wander

|Jan 08, 2025

Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER).

Laura M Spring, Lauren Scarpetti, Arielle J Medford

|Jan 02, 2025

TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer.

Rachel O Abelman, Bogang Wu, Haley Barnes

|Jul 26, 2024

Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial.

Rebecca A Dent, Sung-Bae Kim, Mafalda Oliveira

|Jun 27, 2024

Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.

Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa

Pageof 5

Frequent Collaborators

12 joint publications

Leif W Ellisen

Dejan Juric

Aditya Bardia

Seth A Wander

Beverly Moy

Minetta Liu

Laura Spring

Amy Comander

Sara M Tolaney

Ian Krop

Frequent Collaborators

12 joint publications

Leif W Ellisen

7 joint publications

Dejan Juric

6 joint publications

Aditya Bardia

6 joint publications

Seth A Wander